Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in
A landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that
In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.
The ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.